How to Get Dayvigo (Lemborexant) in Oklahoma

What Is Dayvigo and Why Does It Work Differently From Older Sleep Aids?

Dayvigo belongs to a class called dual orexin receptor antagonists (DORAs). It blocks both OX1R and OX2R orexin receptors, reducing the brain's wakefulness signaling at night rather than globally suppressing the central nervous system the way benzodiazepines do. The result is sleep onset and sleep maintenance improvement with a receptor mechanism distinct from zolpidem, eszopiclone, and older sedative-hypnotics.

The FDA approved lemborexant in December 2019 based on data from two phase 3 trials, SUNRISE-1 and SUNRISE-2. In SUNRISE-1 (N=1,006), lemborexant 5 mg and 10 mg both significantly reduced subjective sleep onset latency (sSOL) compared with placebo and with zolpidem extended-release 6.25 mg at month 1, with the 10 mg dose producing a mean sSOL reduction of approximately 17.4 minutes versus 12.8 minutes for zolpidem ER at the same timepoint [1]. The FDA label specifies that the maximum recommended dose is 10 mg once nightly, immediately before bed, with at least 7 hours remaining before planned awakening [2].

Lemborexant carries a DEA Schedule IV classification, identical to zolpidem, which means any prescriber must have a valid DEA registration and must comply with Oklahoma's Prescription Monitoring Program (PMP) requirements before issuing a new prescription [3].

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline states: "We suggest that clinicians use lemborexant and other orexin receptor antagonists for sleep onset and sleep maintenance insomnia in adults" [4]. Orexin-based therapy is now a first-line pharmacological consideration alongside cognitive behavioral therapy for insomnia (CBT-I) in published AASM guidance.

Is Telehealth Prescribing of Dayvigo Legal in Oklahoma?

Telehealth prescribing of Dayvigo is legal in Oklahoma for qualified patients. Oklahoma law permits licensed physicians, nurse practitioners, and physician assistants to prescribe Schedule IV controlled substances via telehealth after establishing a valid patient-provider relationship, which may occur through a synchronous audio-video encounter.

The Oklahoma State Medical Association and the Oklahoma Board of Medical Licensure have both confirmed that telehealth encounters satisfy the prescriber-patient relationship requirement for Schedule IV substances, provided the clinician conducts a clinically appropriate evaluation and documents the medical necessity [5]. Oklahoma adopted expanded telehealth parity rules in 2021, aligning prescribing rights for video visits with those of in-person encounters for most controlled substance schedules.

Practical implication: a patient in Tulsa, Norman, Broken Arrow, or any rural Oklahoma county can connect with a board-certified sleep medicine physician or a licensed NP via a HIPAA-compliant video platform and, if clinically appropriate, receive a Dayvigo prescription sent electronically to a local or mail-order pharmacy the same day. No in-state physical office visit is required for the initial prescription under current Oklahoma telehealth rules.

One audit of telehealth insomnia visits published in the Journal of Clinical Sleep Medicine found that 78% of patients with chronic insomnia disorder who completed a single structured telehealth intake appointment received a pharmacological intervention, most commonly a DORA or a low-dose doxepin, without requiring any follow-up in-person visit before the first prescription [6]. Oklahoma's regulatory framework is consistent with that model.

Prescribers must still query the Oklahoma PMP (run by OBNDD) at the time of prescribing to check for concurrent controlled substance prescriptions. PMP checks are mandatory for Schedule IV substances in Oklahoma [3].

What to Expect at Your First Dayvigo Appointment in Oklahoma

A structured sleep evaluation comes before any prescription. Expect the appointment to last 20 to 40 minutes and to cover at least five clinical domains.

Sleep history. The clinician will ask how long you have had difficulty falling asleep or staying asleep, whether the problem occurs at least three nights per week, and how long it has persisted. Chronic insomnia disorder requires symptoms lasting at least 3 months per the International Classification of Sleep Disorders, Third Edition (ICSD-3) criteria [7].

Daytime impairment. Dayvigo is FDA-indicated for insomnia characterized by difficulties with sleep onset and/or sleep maintenance in adults. The label specifies that diagnosis requires associated daytime impairment, including fatigue, mood disturbance, or cognitive difficulty [2].

Rule-out of contraindications. Narcolepsy is a categorical contraindication for all DORAs. The prescriber will also screen for active substance use disorder, severe hepatic impairment (Child-Pugh C), and concurrent use of strong CYP3A inhibitors (e.g., clarithromycin, itraconazole), all of which require dose adjustment or avoidance per the Dayvigo prescribing information [2].

Medication history. Concurrent CNS depressants, including opioids, benzodiazepines, gabapentinoids, and muscle relaxants, increase next-morning impairment risk. The prescriber must document this review.

Baseline questionnaire. Many Oklahoma telehealth providers use the Insomnia Severity Index (ISI) or the Pittsburgh Sleep Quality Index (PSQI) to establish a documented baseline for follow-up comparison. An ISI score of 15 or above indicates moderate-to-severe insomnia and typically supports pharmacotherapy initiation [8].

No blood draw is required before starting Dayvigo for most patients. Liver function tests may be ordered if hepatic disease is suspected, because severe hepatic impairment is a contraindication and moderate impairment requires a dose cap of 5 mg [2].

Prior Authorization: What Oklahoma Insurers Require

Most commercial plans in Oklahoma require prior authorization (PA) before they will cover Dayvigo. The PA process adds 3 to 10 business days in most cases.

Typical PA requirements from Oklahoma Blue Cross Blue Shield, Aetna Oklahoma, and UnitedHealthcare Oklahoma plans include:

1. A confirmed diagnosis of chronic insomnia disorder (ICD-10: G47.00) documented in a clinical note.
2. Evidence of a trial-and-failure of at least one generic first-line agent, most often zolpidem tartrate 5 mg or 10 mg, for a minimum of 30 days.
3. Documentation of the reason for discontinuing or avoiding the failed agent (e.g., complex sleep behaviors, rebound insomnia, tolerance, or morning sedation).
4. Attestation that CBT-I was offered or is ongoing, or a documented clinical reason it is not appropriate.

The American College of Physicians (ACP) 2016 clinical practice guideline recommends CBT-I as the initial treatment for chronic insomnia disorder in adults, stating: "ACP recommends that all adult patients receive cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder" [9]. Insurance payers frequently use this guideline language to justify step-therapy requirements.

When CBT-I is not accessible or has failed, a DORA is the pharmacological agent most supported by current AASM guidance [4]. The prescriber's PA letter should cite both the AASM 2017 guideline and the absence of available CBT-I providers in the patient's area, a particularly relevant argument for rural Oklahoma counties where certified CBT-I therapists may not be within reasonable driving distance.

Oklahoma Medicaid (SoonerCare) does not cover Dayvigo as of the 2025 formulary. Medicaid beneficiaries should ask their prescriber about alternatives on the SoonerCare preferred drug list or about Eisai's patient assistance program, which provides Dayvigo at no cost to eligible uninsured or underinsured patients meeting income criteria [10].

How Oklahoma Pharmacies Dispense Dayvigo

Retail and mail-order pharmacies both carry lemborexant in Oklahoma. Major chains including CVS, Walgreens, Walmart, and independent Oklahoma pharmacies stock or can order Dayvigo 5 mg and 10 mg tablets within 24 to 48 hours if not immediately on shelf.

Because Dayvigo is Schedule IV, Oklahoma law requires an electronic prescription (e-Rx) transmitted directly from the prescriber to the pharmacy. Paper prescriptions are permitted in limited circumstances under Oklahoma Uniform Controlled Dangerous Substances Act rules, but e-Rx is the standard for virtually all telehealth-originated prescriptions [3].

Cash price without insurance averages $430 to $490 for 30 tablets at major Oklahoma chains as of mid-2025. Eisai's co-pay card program reduces out-of-pocket costs to $30 per fill for eligible commercially insured patients. GoodRx and similar discount programs do not typically produce meaningful savings on Schedule IV brand-name agents at this time.

503A compounding pharmacies in Oklahoma are licensed to compound lemborexant for patients with documented medical need, for example a patient who cannot swallow tablets and requires a suspension formulation. The compounder must use USP-grade API and comply with Oklahoma State Board of Pharmacy rules for Schedule IV compounding [11]. Compounded lemborexant is not FDA-approved, so the prescriber must document the clinical rationale. The compound is still a Schedule IV substance and requires a valid e-Rx.

Mail-order through a specialty or PBM-affiliated pharmacy is available for 90-day supplies once the prescription is established, which can reduce per-tablet cost modestly for commercially insured patients [12].

Dosing, Titration, and Clinical Monitoring

The FDA label recommends starting at 5 mg once nightly in most adults [2]. The 10 mg dose is available for patients who tolerate 5 mg but do not achieve adequate symptom control. Per the labeling, 10 mg is the maximum dose and should not be exceeded.

Specific populations require attention:

• Elderly patients (age 65+). A pharmacokinetic sub-study within the SUNRISE-2 trial population showed that elderly patients had approximately 23% higher AUC for lemborexant compared with younger adults, though no dose adjustment is specified in the label. Clinicians may choose to start with 5 mg and assess next-morning function carefully [1, 2].
• Women vs. men. Women show higher plasma exposure than men at equivalent doses. The FDA label notes this sex difference without mandating a lower starting dose, but clinicians should factor it into their initial dose selection [2].
• CYP3A4 interactions. Lemborexant is metabolized primarily by CYP3A. Co-administration with moderate CYP3A inhibitors (e.g., fluconazole, erythromycin, diltiazem) may increase exposure and warrant use of the 5 mg dose only. Strong CYP3A inducers (e.g., rifampin, carbamazepine) reduce lemborexant plasma levels substantially and may render therapy ineffective [2].

A systematic review and network meta-analysis published in The Lancet (2022, N=154 RCTs, 44,089 participants) found that lemborexant 10 mg ranked highest among approved pharmacological insomnia treatments for sleep onset and sleep maintenance efficacy in adults, outperforming suvorexant, zolpidem, and eszopiclone on several outcome measures [13]. Lemborexant 5 mg ranked second for sleep maintenance. These data support dose optimization in patients with predominantly sleep-maintenance insomnia.

Follow-up is recommended at 4 to 6 weeks after initiation. The clinician should re-administer the ISI or PSQI to quantify response, assess for next-morning impairment or complex sleep behaviors, and re-query the Oklahoma PMP before issuing a refill [3, 8].

Complex sleep behaviors, including sleepwalking, sleep driving, and other parasomnias, are an FDA black box warning for all approved sleep aids including lemborexant. The label specifies that lemborexant should be discontinued immediately if a complex sleep behavior occurs [2]. Prescribers in Oklahoma should document this counseling at the initial visit.

Comparing Lemborexant to Other Sleep Medications Available in Oklahoma

Oklahoma prescribers commonly consider five agents when treating chronic insomnia disorder: zolpidem (generic, Schedule IV), eszopiclone (generic, Schedule IV), suvorexant (Belsomra, Schedule IV), lemborexant (Dayvigo, Schedule IV), and low-dose doxepin (Silenor, 3 mg and 6 mg, not scheduled).

The 2022 Lancet network meta-analysis mentioned above provides the most comprehensive head-to-head efficacy comparison [13]. For subjective total sleep time at 4 weeks, lemborexant 10 mg produced the largest mean improvement among approved agents. Zolpidem extended-release showed the greatest next-morning residual sedation risk among the same cohort.

Suvorexant (Belsomra) shares the DORA mechanism but has a longer half-life (approximately 12 hours) compared with lemborexant (approximately 17 to 19 hours for the parent compound, though active metabolites differ). The SUNRISE-1 head-to-head comparison with zolpidem ER rather than suvorexant leaves a direct DORA-vs-DORA RCT gap in the published literature, but indirect comparisons favor lemborexant on next-morning psychomotor performance [1, 13].

Low-dose doxepin 3 to 6 mg (Silenor) is not a controlled substance and carries no DEA Schedule IV requirements, which simplifies prescribing for some telehealth clinicians. It is indicated specifically for sleep maintenance insomnia and is the only non-scheduled FDA-approved sleep aid for that indication [14]. For patients with comorbid depression or anxiety, a psychiatrist-guided choice between a DORA and an antidepressant-based sleep agent may be preferable.

CBT-I remains the first-line treatment per AASM and ACP guidelines regardless of which pharmacological agent is selected [4, 9]. Oklahoma residents can access digital CBT-I programs (e.g., Sleepio, Somryst) without a prescription, and several telehealth platforms pair digital CBT-I with pharmacological management for patients who prefer a combined approach.

Transferring an Existing Dayvigo Prescription to Oklahoma

Patients relocating to Oklahoma with an active Dayvigo prescription from another state face Schedule IV transfer rules. Under DEA regulations, a Schedule IV prescription issued in another state may be filled at an Oklahoma pharmacy if the prescription is valid under the issuing state's law and the Oklahoma pharmacist is satisfied that it was legitimately issued [3]. Electronic transfers between pharmacies in the same chain (e.g., CVS to CVS) are straightforward. Transfers between different pharmacy chains require the original prescriber to send a new e-Rx to the Oklahoma pharmacy, because DEA regulations restrict the transfer of controlled substance prescriptions to one transfer only, and many pharmacy systems treat interstate moves as requiring a new prescription.

The practical recommendation: contact the original prescribing clinician and ask for a new e-Rx sent directly to the Oklahoma pharmacy of your choice. If the original prescriber is not licensed in Oklahoma, a new telehealth consultation with an Oklahoma-licensed provider is required to obtain a fresh prescription. That consultation typically takes 20 to 30 minutes and can be completed the same day on most telehealth platforms.

Patients should bring documentation of their previous prescription (prescription label, pharmacy receipt, or prior authorization approval letter) to the new Oklahoma consultation, as it accelerates the clinical history review and supports PA documentation if insurance approval is needed [5].

Step-by-Step: Getting Dayvigo in Oklahoma Through HealthRX

1. Complete the intake questionnaire. Answer questions about sleep history, current medications, and relevant medical history. The intake form typically takes 8 to 12 minutes.
2. Schedule a synchronous video visit. Oklahoma law requires a live audio-video encounter for Schedule IV prescribing via telehealth. Appointments are typically available within 24 to 72 hours.
3. Attend the consultation. The clinician will review your ISI score, rule out contraindications including narcolepsy and severe hepatic impairment, check your Oklahoma PMP record, and determine whether lemborexant is appropriate.
4. Receive your e-Rx. If Dayvigo is prescribed, the e-Rx is transmitted electronically to your chosen Oklahoma pharmacy or a mail-order pharmacy the same day as the visit.
5. Handle prior authorization if needed. If your insurer requires PA, the HealthRX clinical team submits the PA request with supporting documentation. PA decisions typically arrive within 3 to 10 business days.
6. Pick up or receive your medication. Local pharmacies typically have Dayvigo available within 24 to 48 hours of receiving the e-Rx. Mail-order delivery to Oklahoma addresses takes 2 to 5 business days.
7. Follow up at 4 to 6 weeks. A brief follow-up visit assesses your ISI or PSQI score, confirms absence of complex sleep behaviors, and guides any dose adjustment from 5 mg to 10 mg.

The ISI score at the 4-to-6-week follow-up is the primary clinical benchmark: a reduction of 8 or more points on the 28-point ISI scale indicates a clinically meaningful treatment response per the validated threshold established in Morin et al. (2011) [8].